淋巴水肿治疗的全球市场 (2023～2030年):各终端用户、产品类型、症状类型、治疗类型的规模、占有率、成长分析、预测

Global Lymphedema Treatment Market Size, Share, Growth Analysis, By End-User, By Product, By Condition Type, By Treatment Type - Industry Forecast 2023-2030

出版日期: 2023年04月22日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格

简介目录

淋巴水肿治疗的市场规模，2021年为7亿8653万美元，2022年为8亿6014万美元，从2023年到2030年的预测期间中预计以9.5％的年复合成长率发展，2030年成长到17亿3,536万美元的规模。

乳癌的发生率上升，淋巴水肿的盛行率上升，市场参与企业引进复数的新产品，技术进步的结果对有效率的产品的需求上升等成为促进淋巴水肿治疗市场成长的主要原因。

本报告提供全球淋巴水肿治疗的市场调查，市场概要，市场的各种影响因素的分析，技术、革新趋势，市场规模的变化、预测，各种区分、各地区的明细，竞争情形，主要企业简介等彙整资讯。

市场概要
市场规模
市场动态
促进因素
机会
阻碍因素
课题
主要的市场洞察
技术分析
价格分析
供应链分析
价值链分析
市场生态系统
IP分析
贸易分析
Start-Ups分析
原料分析
革新矩阵
开发中产品的分析
宏观经济指标
主要投资分析
主要成功因素
竞争的程度
市场动态及预测
市场动态
促进因素
机会
阻碍因素
课题
法规情形
波特分析
未来阻碍相关Skyquest的特别洞察
全球淋巴水肿治疗市场:各终端用户
市场概要
医院
门诊病人手术中心
专门诊所
其他
全球淋巴水肿治疗市场:各产品
市场概要
加压绷带
压力袜
空气压迫设备
其他
全球淋巴水肿治疗市场:各症状类型
市场概要
癌症
心血管疾病
发炎性疾病
其他
全球淋巴水肿治疗市场:各治疗类型
市场概要
压迫疗法
手术
药物疗法
雷射治疗
其他
全球淋巴水肿治疗市场:各地区
市场概要
北美
美国
加拿大
欧洲
德国
西班牙
法国
英国
其他的欧洲
亚太地区
中国
印度
日本
韩国
其他的亚太地区
南美
巴西
其他的南美
中东、非洲
GCC各国
南非
其他的中东、非洲
竞争情形
主要5家公司的比较
主要企业的地位
主要企业的采用策略
主要成功策略
市场上最近的活动
主要企业的市场占有率
主要企业简介
Bio Compression Systems
Tactile Medical
Medi
Lympha Press
Sigvaris
BSN Medical
L&R USA Inc.
Devon Medical Products
3M Health Care
JOBST USA
Thuasne
Wright Therapy Products
BioHorizons IPH, Inc.
Haddenham Healthcare
ArjoHuntleigh
Paul Hartmann
Bioventus
Baxter International Inc.
CircAid Medical Products, Inc.
Essity Aktiebolag

简介目录

Product Code: SQSG35G2016

Lymphedema Treatment Market size was valued at USD 786.53 million in 2021 and is poised to grow from USD 860.14 million in 2022 to USD 1735.36 million by 2030, growing at a CAGR of 9.5% in the forecast period (2023-2030).

A condition known as lymphedema is characterised by abnormal swelling of the body brought on by lymphocytosis as a result of lymphatic system failure. The lower extremity is affected 90% of the time, the upper extremity 10%, and the genitalia 1%. The most common cause of lymphedema (filariasis) is an infection brought on by the parasite Wuchereria bancrofti. Lymphedema is among the most dreaded and unlucky side effects of breast cancer treatment. According to a National Centre for Biotechnology Information (NCBI) research, 40 percent of breast cancer patients experienced lymphedema. The primary factors driving the growth of the lymphedema treatment market are the rising incidence of breast cancer, the rising prevalence of lymphedema, the introduction of several new products by prominent market participants, and the rising need for efficient products as a consequence of technological advancements.

The lymph node draining condition known as lymphedema can appear in cancer patients before or after treatment, according to the US Department of Health and Human Services. For instance, it has been noted that it may occur immediately or up to 30 years after breast cancer treatment. Additionally, 80% of patients start showing symptoms 3 years after surgery, with the remaining 20% developing edoema at a rate of 1% every year. Additionally, after the treatment of gynecologic cancer, a sizeable patient population, primarily women, develops lower-limb lymphedema, with vulvar cancer survivors having the highest frequency (37%) and ovarian cancer survivors having the lowest prevalence (7%). Additionally, the incidence of arm lymphedema varied from 8% to 56% two years after surgery. According to the Alliance Z 1071 longitudinal substudy of the American College of Surgeons Oncology Group (ACOSOG), participants in breast cancer trials report a 3-year cumulative incidence of arm edoema and arm heaviness. Cutting edge and very effective cancer treatment options aid in lowering the risk of lymphedema. The major players in the market for cancer therapeutics are working very hard to introduce innovative products as a result.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lymphedema Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

Based on end-user, the market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. Based on product, the market is segmented into compression bandages, compression stockings, pneumatic compression devices, others. Based on affected area, the market is segmented into Genital, Lower Extremity, Upper Extremity and Others. Based on age group, the market is segmented into adult and geriatric. Based on route of administration, the market is segmented into Oral, Injectable and Others. Based on type, the market is segmented into primary and secondary lymphedema. Based on condition type, the market is segmented into cancer, cardiovascular diseases, inflammatory diseases, and others. Based on treatment type, the market is segmented into Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others. Based on region, the global market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Driver

As cases of breast cancer and lymphedema rise, it is projected that the market for lymphedema treatments would expand. The likelihood of developing cancer is predicted to rise, creating tremendous opportunity for market expansion. Increasing health spending and growing investments in drug discovery research and development have increased the demand for healthcare facilities. The development of novel lymphedema treatment options is also projected to support market expansion throughout the forecasted period.

The market expansion in the upcoming years is projected to be accelerated by technological developments in lymphedema treatment methods. Additionally, the rise of the market is undoubtedly facilitated by the government's favourable programmes and the reimbursement requirements.

Restraint

Despite advances in technology, there is still no permanent treatment for lymphedema, which is anticipated to limit market growth.

The high cost of procedures and treatments is anticipated to restrict market growth.

Market Trends

As more people experience the ailment, the market for lymphedema treatments is anticipated to grow. Additionally, innovative and cutting-edge treatments are being developed at an exponential rate to lower risk throughout treatment as the disease develops further. Increasing healthcare spending is also predicted to spur industry growth and an increase in healthcare innovation. Additionally, pharmaceutical companies are encouraging worldwide business globalisation by introducing cutting-edge medical equipment.